Hydralazine Remedica (Hydralazine)

Hydralazine Remedica is indicated for several cardiovascular conditions where direct arterial dilation is beneficial, particularly when rapid reduction of peripheral resistance is required.

• Primary treatment of moderate to severe essential hypertension.
• Adjunctive therapy for chronic heart failure with reduced ejection fraction.
• Management of hypertension that is refractory to first‑line agents.
• Short‑term control of blood pressure in pre‑eclampsia (off‑label, physician‑guided).
• Used in combination with β‑blockers or diuretics to achieve target blood pressure.
• Pre‑operative blood pressure optimization in patients undergoing cardiac surgery.

• Hydralazine acts directly on arteriolar smooth muscle by interfering with intracellular calcium handling and inhibiting the release of endothelin, leading to relaxation of vascular smooth muscle. This vasodilatory effect reduces systemic vascular resistance without significant effect on cardiac output. The drug’s action is independent of autonomic receptors, allowing it to lower blood pressure even when sympathetic tone is high and improves tissue perfusion.

Like most antihypertensive agents, Hydralazine Remedica may cause adverse reactions that vary in frequency and severity.

Common

• Headache, often described as throbbing and may worsen with rapid dose escalation.
• Tachycardia, typically a mild increase in heart rate that can be transient.
• Flushing, a warm sensation and reddening of the skin, especially on the face and neck.
• Nausea or mild gastrointestinal discomfort, which may improve with food.

Serious

• Drug‑induced lupus erythematosus, presenting with joint pain, fever, and a characteristic rash.
• Severe hypotension, marked drop in blood pressure that can cause dizziness or fainting.
• Myocardial ischemia or angina, particularly in patients with pre‑existing coronary artery disease.

When prescribing Hydralazine Remedica, clinicians should evaluate several safety considerations to minimize risk.

• Pregnancy category is unknown; use only if the potential benefit justifies the potential risk to the fetus.
• Monitor for signs of drug‑induced lupus, especially in patients with a history of autoimmune disease.
• Adjust dose cautiously in patients with renal or hepatic impairment.
• Elderly patients may be more susceptible to hypotension and should be started at lower doses.
• Regular blood pressure monitoring is essential to avoid excessive hypotension.
• Contraindicated in patients with known hypersensitivity to hydralazine or any component of the formulation.

Hydralazine Remedica can affect the pharmacodynamics or pharmacokinetics of other medicines, requiring attention to potential interactions.

Avoid

• Concurrent use with other potent vasodilators (e.g., nitroglycerin) that may precipitate severe hypotension.
• Combination with high‑dose β‑blockers without careful monitoring, as reflex tachycardia may be blunted.

Use with caution

• Diuretics, which can amplify the blood‑pressure‑lowering effect and increase the risk of electrolyte imbalance.
• ACE inhibitors or ARBs, where additive hypotensive effects may occur.
• Drugs that can trigger lupus‑like reactions (e.g., procainamide), increasing the risk of autoimmune manifestations.
• Medications metabolized by the liver enzyme CYP1A2, as hydralazine may alter their clearance.